![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, August 12, 2020 12:55:32 PM
https://www.einnews.com/pr_news/523679070/n8-medical-announces-its-cerashield-coating-inhibits-covid-19-virus-growth-on-endotracheal-tubes
NEWS PROVIDED BY
N8 Medical
August 11, 2020, 12:45 GMT
Photo of endotracheal tube extubated from patient with COVID-19. Green coloration of the tube is indicative of extensive bacterial fouling.
Reduction in COVID-19 Virus Exposure May Benefit Patients, Doctors and Nurses
DUBLIN, OHIO, UNITED STATES, August 11, 2020 /EINPresswire.com/ -- N8 Medical, LLC, a privately held biotechnology company, today announced that its CeraShield™ coated endotracheal tubes significantly reduced the growth of COVID-19 virus in recent testing. The testing shows statistically significant reduction in the growth of the COVID-19 virus on the tube surface in 60 minutes. Ordinary uncoated endotracheal tubes either allowed increased virus growth or had no inhibitory effect.
“Recent COVID-19 research has shown that the virus is able to adhere to plastic surfaces and is also able to be aerosolized and inhaled by people in close proximity, including doctors and nurses” says Ronald Bracken, President and Chief Operating Officer of N8. Mr. Bracken added “Most endotracheal tubes are made of plastic. COVID-19 patients who become mechanically ventilated will require use of one of these plastic tubes to connect to the mechanical ventilator.”
Ordinary endotracheal tubes lack any antifouling protection. Within hours, these tubes become breeding grounds for biofilms, pathogenic bacteria, fungi and viruses. This often leads to deadly secondary infections that can be multidrug resistant, and other complications.
Dr. Michael Niederman, a leading expert in respiratory infections and a member of N8 Medical’s Scientific Advisory Board stated “Anything that can significantly reduce the presence of pathogens on the surface of an endotracheal tube is a welcome advance that has the potential to reduce a patient’s length of stay, reduce antibiotic and drug use and improve patient’s outcomes. I look forward to the results of clinical studies to evaluate the magnitude of the potential benefit of the CeraShield™ endotracheal tube in COVID-19 patients.”
N8 Medical has previously completed first-in-human clinical trials in non-COVID, mechanically ventilated patients with no adverse effects. Those clinical studies have shown that the CeraShield™ endotracheal tubes were able to completely prevent pathogenic bacterial and fungal biofilm growth of tube surfaces.
A leading market research firm recently awarded N8 Medical’s CeraShield™ endotracheal tube “Product Innovation of the Year” award for its CeraShield™ technology platform for prevention of hospital-acquired infections. FDA has designated the CeraShield™ endotracheal tube as a “breakthrough device.”
The company previously announced that Health Canada has granted Emergency Use Authorization for use of the CeraShield™ endotracheal tube in COVID-19 patients who require mechanical ventilation in Canada. The Company has pending EUA request with the FDA and with the MHRA in the UK. Clinical studies are currently planned in COVID-19 hotspots. Hospitals that have an interest in participating in clinical studies are encouraged to contact N8 Medical at covid@n8medical.com.
ABOUT N8 MEDICAL
N8 Medical, LLC (www.N8Medical.com), headquartered in Dublin, Ohio, is a rapidly-growing, privately-held clinical stage biotechnology company developing a platform of anti-fouling medical devices designed to have significant, life-saving clinical impact through reduction of infection, related complications and mortality. Key publications are available at www.N8Medical.com.
"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854
Recent HYDI News
- Hydromer Announces Attainment of ISO 13485 Certification • InvestorsHub NewsWire • 06/17/2024 01:22:57 PM
- Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • InvestorsHub NewsWire • 06/05/2024 02:24:00 PM
- Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • InvestorsHub NewsWire • 04/29/2024 01:10:23 PM
- Hydromer, Inc. Wraps Up a Successful 2023, Including Restructuring, Contract Extensions, and the Launch of New Innovations • InvestorsHub NewsWire • 01/16/2024 09:07:55 PM
- Hydromer, Inc. Unveils Rebranding Initiatives Reflecting Its Transformation and Focus on Growth and Innovation • InvestorsHub NewsWire • 12/13/2023 02:44:12 PM
- Hydromer Inc. Announces Formation of its Scientific Advisory Board with the Appointment of its First Member Eric Becktel • InvestorsHub NewsWire • 10/24/2023 01:48:33 PM
- Hydromer, Inc. Releases Letter to Shareholders from Chairman Braeden Lichti • InvestorsHub NewsWire • 09/14/2023 05:15:07 PM
- Hydromer Inc. Marks a Formidable Presence: Set to Exhibit at BIOMEDevice Conferences in Boston and Santa Clara • InvestorsHub NewsWire • 08/25/2023 07:24:01 PM
- Hydromer Inc. Shares Message from CEO Michael E. Torti • InvestorsHub NewsWire • 07/31/2023 06:23:34 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM